Mayo Foundation for Medical Education and Research

S Keith Anderson

Evanthia Galanis

Cheyne B Kurokawa

Ianko D Iankov

Robert B Jenkins

George G Klee

Karla V Ballman

Eric J Bergstralh

Bruce W Morlan

Thomas M Kollmeyer

Tohru Nakagawa

This document relates to materials and methods involved in treating cancer. For example, materials and methods for using one or more oncolytic viruses (e.g., one or more oncolytic viruses) to treat cancer in a mammal (e.g., a human) identified as having a cancer likely to respond to oncolytic virotherapy are provided.

Materials and methods for treating cancer

This document provides methods and materials involved in treating cancer. For example, methods and materials for using an inhibitor of UFM1 activity or expression and/or an inhibitor of UFL1 activity or expression to reduce a cancer cell's ability to carry out a DDR, thereby increasing the sensitivity of cancer cells to treatment with a DNA damaging therapy such as radiation or chemotherapy, are provided.

This document provides methods and materials related to assessing male mammals (e.g., humans) with prostate cancer. For example, methods and materials for predicting (1) which patients, at the time of PSA reoccurrence, will later develop systemic disease, (2) which patients, at the time of retropubic radial prostatectomy, will later develop systemic disease, and (3) which patients, at the time of systemic disease, will later die from prostate cancer are provided.

Biomarker panels for predicting prostate cancer outcomes

Growing community of inventors

Rochester, MN, United States of America

S Keith Anderson